Skip to content
Menu

Absci Corporation ABSI

Full chart Compare
Set alert

Price alert · ABSI

All alert types
7.65 USD -0.51 (-6.25%)

As ofNov 20, 2026, 1:25 PM EST

7.45 Day range 7.67
2.24 52-week range 12.55
YTD
+119.20%
1 year
+176.17%

5D -0.24 (-3.11%)

7.5088.50MonTueWedThuFri7.48
Market cap
1.32B
Revenue (ttm)
1.49M
EPS (ttm)
-0.79
Shares out
172.75M
Forward P/E
-10.55
YTD return
+119.20%
1-year return
+176.17%
50-day average
9.59
200-day average
6.90
Enterprise value
1.24B
Volume
2.13M
Avg volume
4.04M
Open
7.63
Previous close
8.16
Day's range
7.45 – 7.67
52-week range
2.24 – 12.55
Beta
2.19
Analysts
Strong Buy
Price target
15.09 (+97.3%)
Earnings date
Mar 23, 2027

Key statistics

Price / sales
947.95
Price / book
6.43
Revenue growth
-19.60%
Free cash flow
-50.90M
Total cash
173.73M
Total debt
3.29M
Return on equity
-58.59%
Short % of float
25.21%

Fundamental scorecard

4 of 25 checks passed on ABSI’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
ABSI Revenue — quarterly 304.00K
ABSI Net income — quarterly -33.30M
ABSI EPS — quarterly -0.19

Earnings

ABSI recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 23, 2027Dec 30, 2026-0.17———
Nov 12, 2026Sep 30, 2026-0.18892-0.190.00-0.57%
Aug 11, 2026Jun 30, 2026-0.19102-0.18+0.01+5.77%
May 7, 2026Mar 31, 2026-0.20-0.19+0.01+5.00%
Mar 24, 2026Dec 31, 2025-0.16-0.23-0.07-43.75%
Nov 12, 2025Sep 30, 2025-0.19-0.20-0.01-5.26%

Upgrades / downgrades

ABSI analyst upgrades and downgrades
DateFirmActionFromTo
Oct 29, 2026Jefferiesinit—Buy
Oct 16, 2026KeybancmainOverweightOverweight
Oct 12, 2026JP MorganmainOverweightOverweight
Oct 12, 2026HC Wainwright & Co.reitBuyBuy
Sep 23, 2026NeedhamreitBuyBuy
Sep 9, 2026LifeSci Capitalinit—Outperform

About Absci Corporation

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
absci.com

News

Your note

Sign in to keep a note on ABSI — it syncs with the Stock Master app.

Insider holders

ABSI insider holders
InsiderRelationLatest transactionDateShares held
BEDRICK TODDOfficerStock Award(Grant)Mar 1, 2026216,942
BUSCH ANDREASOfficerPurchaseMar 11, 2026421,446
JONASSON ZACHARIAHChief Financial OfficerStock Award(Grant)Mar 1, 2026499,783
MCCLAIN SEANChief Executive OfficerStock Award(Grant)Mar 1, 20268,715,450
MCGINNIS KAREN KDirectorStock Award(Grant)Jun 3, 202648,420
PANGALOS MENELAS NDirectorStock Award(Grant)Jun 3, 2026242,408

Institution ownership

ABSI institution ownership
Holder% heldSharesValueReported
FMR, LLC14.90%25,742,031210.05MSep 29, 2026
Blackrock Inc.8.39%14,500,696118.33MSep 29, 2026
ARK Investment Management, LLC6.91%11,928,91797.34MSep 29, 2026
State Street Corporation4.90%8,460,58969.04MSep 29, 2026
Vanguard Capital Management LLC4.08%7,042,51357.47MSep 29, 2026
Redmile Group, LLC3.86%6,671,37754.44MSep 29, 2026

Fund ownership

ABSI fund ownership
Holder% heldSharesValueReported
ARK ETF Trust-ARK Genomic Revolution ETF6.30%10,881,39488.79MOct 30, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund4.64%8,022,96765.47MSep 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.86%4,946,40240.36MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.55%4,407,68535.97MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.25%3,888,88931.73MSep 29, 2026
Columbia Acorn Trust-Columbia Acorn Fund1.67%2,889,06623.57MJun 29, 2026